Implementation of precision cancer medicine and economic evaluation for Health Technology Assessment (HTA) – what are the challenges and how do we address them?

The PRIME-ROSE kick-off took place in Oslo on September 19-20 and gathered around 70 participants from different partners across Europe.

Testbed Sweden Precision Cancer is attending the PRIME-ROSE kick-off in Oslo right now!

We are looking forward to participating at the Nordic Precision Cancer Medicine conference in Oslo during next week.

PRIME-ROSE - A European precision cancer medicine trial network and implementation initiative funded by the EU Cancer Mission. The project was approved by the European Commission om April 23 2023.

We are excited to be part of the growing DLCT (DRUP-Like Clinical Trial) Community and are looking forward to start working on the implementation of precision medicine for all patients in Europe!

Combining Expertise Across Borders to Promote Precision Cancer Medicine in Europe. PRIME-ROSE is a Horizon Europe Mission on Cancer project with 24 partners from altogether 18 European countries. Moreover, PRIME-ROSE is part of the Cancer Mission cluster of projects on Diagnosis and Treatment.

Great meeting with European Medicines Agency discussing the PRIME-ROSE and PCM4EU - Personalised Cancer Medicine for all EU citizens projects!

PRIME-ROSE - A European precision cancer medicine trial network and implementation initiative funded by the EU Cancer Mission. The project was approved by the European Commission om April 23 2023.